Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Moreau, P;Joshua, D.;Chng, W. J.;Palumbo, A.;Goldschmidt, H.;Hájek, R.;Facon, T.;Ludwig, H.;Pour, L.;Niesvizky, R.;Oriol, A.;Rosiñol, L.;Suvorov, A.;GAIDANO, Gianluca;Pika, T.;Weisel, K.;Goranova Marinova, V.;Gillenwater, H. H.;Mohamed, N.;Aggarwal, S.;Feng, S.;Dimopoulos, M. A.

2017-01-01